Implant Offers Lasting Hope for Severe Depression

Hope is emerging for individuals with severe, treatment-resistant depression, as a major clinical trial indicates that a small implanted device, known as vagus nerve stimulation (VNS), can provide lasting benefits. The RECOVER trial, involving 493 participants in the US, focused on patients who had endured depression for decades and failed numerous treatments.

For those who received active VNS therapy, significant improvements were observed. After 12 months, 69% experienced meaningful symptom reduction, and crucially, over 80% maintained or enhanced these benefits by the 24-month mark. A remarkable one in five patients achieved complete remission from depressive symptoms after two years, a result rarely seen in studies of this patient population.

Further analysis revealed that even individuals showing no significant benefit in the first year sometimes experienced improvement by the second year, suggesting VNS may require more time to take effect for some. The U.S. FDA approved VNS for treatment-resistant depression in 2005, though its precise mechanism remains unclear. These findings aim to inform coverage decisions by the U.S. Centers for Medicare and Medicaid Services, which currently does not cover the therapy.